Ultragenyx Pharmaceutical Inc. (RARE)
Health Care ยท Pharmaceutical Preparations
Ultragenyx Pharmaceutical Inc. (RARE) is listed on Nasdaq, where its shares have traded since January 31, 2014. SentiSense covers Ultragenyx Pharmaceutical Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Emil D. Kakkis is its chief executive officer. The company reports 1,371 employees, and its corporate website is www.ultragenyx.com.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 303 institutions reported holding RARE, with 106.7 million shares worth $3.6 billion in aggregate. The largest reported holders were Vanguard, BlackRock and Rtw Investments. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on RARE
- RARE sentiment: whether news and social coverage of Ultragenyx Pharmaceutical Inc. leans bullish or bearish, and the stories driving it.
- RARE ownership: all 303 reporting institutions, plus insider and congressional trades.
- RARE financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Ultragenyx Pharmaceutical Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions.
What sector is RARE in?
SentiSense classifies Ultragenyx Pharmaceutical Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does RARE stock trade?
Ultragenyx Pharmaceutical Inc. (RARE) is listed on Nasdaq, where its shares have traded since January 31, 2014.
Who is the CEO of Ultragenyx Pharmaceutical Inc.?
Emil D. Kakkis is the chief executive officer of Ultragenyx Pharmaceutical Inc..